Company news
Cullinan Therapeutics, Inc. news in 2022
Cullinan Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 13, 2022
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
November 1, 2022
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
October 24, 2022
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
September 6, 2022
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
August 14, 2022
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 9, 2022
Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
July 31, 2022
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
July 4, 2022
Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
June 22, 2022
Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
May 30, 2022
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
May 25, 2022
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
May 18, 2022
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 15, 2022
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
May 11, 2022
Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
April 26, 2022
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
April 4, 2022
Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
March 27, 2022
Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
March 16, 2022
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 16, 2022
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
March 7, 2022
Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors
February 27, 2022
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
January 9, 2022
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
January 3, 2022
Decks in 2022
- Cullinan Oncology — Corporate Update (May 2022)
Corporate update · 10 slides · May 12, 2022